Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome

Klion, 2009, Hypereosinophilic syndrome: current approach to diagnosis and treatment, Annu Rev Med, 60, 293, 10.1146/annurev.med.60.062107.090340

Chusid, 1975, The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature, Medicine (Baltimore), 54, 1, 10.1097/00005792-197501000-00001

Fauci, 1982, NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations, Ann Intern Med, 97, 78, 10.7326/0003-4819-97-1-78

Roufosse, 2007, Lymphocytic variant hypereosinophilic syndromes, Immunol Allergy Clin North Am, 27, 389, 10.1016/j.iac.2007.07.002

Cogan, 1994, Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome, N Engl J Med, 330, 535, 10.1056/NEJM199402243300804

Simon, 1996, Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia, J Exp Med, 183, 1071, 10.1084/jem.183.3.1071

Simon, 1999, Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia, N Engl J Med, 341, 1112, 10.1056/NEJM199910073411503

Vaklavas, 2007, “Idiopathic” eosinophilia with an Occult T-cell clone: prevalence and clinical course, Leuk Res, 31, 691, 10.1016/j.leukres.2006.10.005

de Lavareille, 2002, High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome, J Allergy Clin Immunol, 110, 476, 10.1067/mai.2002.127003

Schandene, 1996, Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells, J Clin Invest, 97, 309, 10.1172/JCI118417

Rothenberg, 2008, Treatment of patients with the hypereosinophilic syndrome with mepolizumab, N Engl J Med, 358, 1215, 10.1056/NEJMoa070812

Greiner, 2002, Effectiveness of capillary electrophoresis using fluorescent-labeled primers in detecting T-cell receptor gamma gene rearrangements, J Mol Diagn, 4, 137, 10.1016/S1525-1578(10)60694-0

Galimberti, 2007, Cell clonality in hypereosinophilic syndrome: what pathogenetic role?, Clin Exp Rheumatol, 25, 17

Helbig, 2009, T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome, Haematologica, 94, 1236, 10.3324/haematol.2008.005447

Ogbogu, 2009, Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy, J Allergy Clin Immunol, 124, 1319, 10.1016/j.jaci.2009.09.022

Wirnsberger, 2006, IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites, Eur J Immunol, 36, 1882, 10.1002/eji.200635972

Kakinuma, 2001, Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity, J Allergy Clin Immunol, 107, 535, 10.1067/mai.2001.113237

Kakinuma, 2003, Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides, J Am Acad Dermatol, 48, 23, 10.1067/mjd.2003.132

Kakinuma, 2003, High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid, Br J Dermatol, 148, 203, 10.1046/j.1365-2133.2003.05066.x

Sekiya, 2002, Increased levels of a TH2-type CC chemokine thymus and activation-regulated chemokine (TARC) in serum and induced sputum of asthmatics, Allergy, 57, 173, 10.1034/j.1398-9995.2002.5720256.x

Yagi, 1997, Wells' syndrome: a pathogenic role for circulating CD4+CD7- T cells expressing interleukin-5 mRNA, Br J Dermatol, 136, 918

Stein, 2008, Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels, J Allergy Clin Immunol, 121, 10.1016/j.jaci.2008.02.033